Industry Longevity Is about to progress to the next level! May cause humans to haveLive longerFor another 10 years by Retro Biosciences. Start up biology company to extend the life expectancy. That was supported after Sam Altman (Sam Altman) CEO of Openai Revealing the progress of the research on the extension of the big life expectancy In the development of tablets that have the potential toResist Alzheimer’s The first human experiment is expected to begin by the end of 2025.
Hope of a new drug Human health revolution
Table of Contents
Joe Betts-lacroix, the CEO of Retro Biosciences, scientist. And entrepreneurs who have created the smallest computer in the world He compared the work he acted like a big revolution in human life. Like the air conditioner that has changed the way that humans cope with hot weather
The past experience made him fascinated. “Change the paradigm” and today he is trying to do the same thing with human biology. Bets-drag Ruaz hopes that one day, biology science will help “to separate aging from disease and deterioration”.
Retro Biosciences was founded in 2021, with an investment of US $ 180 million from Sam Altman, and by the end of 2025, the company will begin to experiment with RTR242 in humans for the first time.
Step first, throw research, study pills, RTR242
This drug aims “Awaken the recycling system” or Autophagy to return to work like when the body is young. This process is responsible for eliminating damaged proteins, broken or unusual in the brain. Which it often happens as we are older Then this system will cause and cause the accumulation of “Kam Saul” that is an important factor of Alzheimer’s and Parkinson’s disease.
“There are many old proteins, mutations and sub -mutations that gradually Accumulated in the cell And the recycling system in the body began to deteriorate as they were older, “Bates-drag Ruaz explained.
For the experiment to start quickly. Retro choose Australia as a trial base. Because there is a phase 1 approval process (safety test) faster than in the United States Currently, the company has already chosen the experimental center and the contract room. And is expected to have the first participants at the end of this year
Challenge the giant rival in Longevity.
But not easy to move forward Because to expand to a large experiment, there is a “reliable result” to attract larger investment. The company aims to up to 1,000 million US dollars for series A.
If Retro can pull the capital as targeted Will make the company step up to the same group as Jeff Bezos of Altos Labs, which is considered a start -up Longevity With the thickest funds in the Silicon Valley. Altos has raised more than 3,000 million US dollars. From famous investors like Yuri Milner, Joe Lonsdale, the co -founder of Palantir and Robert Nelson, the founder of Arch Venture.
RTR242 is not the only research project of Retro, but one of the three pillars of the company. All of which aims “Returning human biology back to younger”. In addition to the Alzheimer’s treatment, Retro also developed other drugs, including
– RTR890: Ya Stem Stem cells, new blood cells from the patient’s own cells. To treat blood diseases like leukemia
– RTR888: Central neurological medication with stem cells
Emphasize the system from the internal For the target to extend the life for another 10 years
What makes RTR242 different from the new version of the drug in the market, such as the EISINLA or Kisunla’s LeQEMBI or Kisunla, instead of focusing on eliminating the accumulated Amloid protein in the brain. This drug is intended. “Restart” Autophagy system to get rid of the cells directly. Especially in the brain
Betting-drag Ruax explained, “If this drug can actually work It will be like pressing the reset button. Clean the brain from the inside. “
Retro’s ultimate goal is not to make people live up to 120 years, but it is to increase the “10 years of strong” for everyone. The company does not mean that the average American’s average life expectancy will move from 78 years, but emphasizing that people will still be strong, bright and quality of life to the end of life.
Bets-drag Ruaz emphasized that “Cancer treatment Will increase the life expectancy of only 3 years. Heart disease can increase the life expectancy of 4 years, but if added for 10 years of good health in general That will be one of the greatest success in medical history. “
AI is a secret assistant. Behind the enormous value research
In addition to research on various drugs, Retro also has a “modern” way to research other matters by using AI as an assistant, as well as working with the Openai of Altman. In August. Both companies have revealed the GPT-4B Micro project, a AI model for “reset cells” in the new body to return to youthful state.
The experiment points out that GPT-4B Micro can increase up to 50 times the program of stem cells compared to the original method. This may be an important step in “Reset cells” which are currently the hottest trend in the Silicon Valley. Because it has the potential to go back to the age of human cells and repair the body that deteriorates
Although the “reset cell” is still in the experiment But it is one of the hottest ways in the Silicon Valley now. Because it may be the key to the human body. Today, Retro chooses to run the game carefully. Through the experiment of RTR242 in humans, which, if successful, may be the beginning of the brain reset And in the future, it may lead to medical science revolutions that can actually increase human health.
Reference: Businessinsider
